Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson’s disease by Naoto Kadoguchi et al.
Kadoguchi et al. BMC Neuroscience 2014, 15:79
http://www.biomedcentral.com/1471-2202/15/79RESEARCH ARTICLE Open AccessMirtazapine has a therapeutic potency in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-induced mice model of Parkinson’s
disease
Naoto Kadoguchi†, Shinji Okabe†, Yukio Yamamura, Misaki Shono, Tatsuya Fukano, Akie Tanabe,
Hironori Yokoyama and Jiro Kasahara*Abstract
Background: Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), shows multiple
pharmacological actions such as inhibiting presynaptic α2 noradrenaline receptor (NAR) and selectively activating
5-hydroxytriptamine (5-HT) 1A receptor (5-HT1AR). Mirtazapine was also reported to increase dopamine release in
the cortical neurons with 5-HT dependent manner. To examine whether mirtazapine has a therapeutic potency
in Parkinson’s disease (PD), we examined this compound in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated mice model of PD.
Results: Male C57BL/6 mice were subjected to MPTP treatment to establish a PD model. Mirtazapine was
administered once a day for 3 days after MPTP treatment. MPTP-induced motor dysfunction, assessed by
beam-walking and rota-rod tests, was significantly improved by administration of mirtazapine. Biochemical
examinations by high performance liquid chromatography and western blot analysis suggested mirtazapine
facilitated utilization of dopamine by increasing turnover and protein expression of transporters, without
affecting on neurodegenerative process by MPTP. These therapeutic effects of mirtazapine were reduced by
administration of WAY100635, an inhibitor for 5HT1AR, or of clonidine, a selective agonist for α2-NAR, or of
prazosin, an inhibitor for α1-NAR, respectively.
Conclusion: Our results showed mirtazapine had a therapeutic potency against PD in a mouse model.
Because PD patients sometimes show depression together, it will be a useful drug for a future PD treatment.
Keywords: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Parkinson’s disease, Mirtazapine, Noradrenergic
and specific serotonergic antidepressant (NaSSA), Serotonin (5-hydroxytryptamine, 5-HT), DopamineBackground
Parkinson’s disease (PD) is a progressive, age-related, neu-
rodegenerative disorder characterized by bradykinesia, rest-
ing tremor and gait disturbance. The major pathological
basis of PD is the death of dopaminergic neurons in the
substantia nigra pars compacta (SNc) and the degener-
ation of their nerve terminals in striatum [1]. It has been
proposed that clinical signs of PD appear at the point when* Correspondence: awajiro@tokushima-u.ac.jp
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article, unless otherwise stated.dopaminergic neuronal cell loss exceeds a critical thresh-
old: 70 – 80% of striatal nerve terminals and 50 – 60% of
the SNc perikaryons [2,3]. As a pharmaceutical treatment,
ʟ-3,4-dihydroxyphenylalanine (ʟ-dopa), supplying the pre-
cursor of dopamine (DA), is the most commonly applied
and alleviates major symptom of PD. For over 40 years,
treatment with ʟ-dopa combined with an inhibitor for per-
ipheral aromatic ʟ-amino acid decarboxylase (AADC) such
as carbidopa had been established as a gold standard for
PD treatment [4,5]. However, long-term treatment with ʟ-
dopa is often complicated by the development of adverse
effects such as drug-induced dyskinesia [6]. There havetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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agonists mostly targeted on D2 class receptor, but their
pharmaceutical potencies are not drastically better than
that of ʟ-dopa. It is essential to develop novel drugs which
can support therapeutic effects of ʟ-dopa with delaying ex-
pression of its side effects, or even solely effective against
PD symptoms.
Serotonergic neurons play an important role in modu-
lating extrapyramidal motor disorders such as PD and
drug-induced parkinsonism [7,8]. Some studies showed
administration of agonists for 1A subtype of serotonin/
5-hydroxytriptamine receptor (5-HT1AR, e.g., 8-hydroxy-
2-(di-n-propylamino)tertraline and tandospirone) sig-
nificantly improved various types of extrapyramidal
symptoms including antipsychotic-induced bradykinesia
and catalepsy, and neurotoxin-induced bradykinesia [9-11].
Therefore, the central serotonergic system is thought
to be one of a favorable drug target for the treatment
of PD. It is a well-known fact that serotonergic as well as
noradrenergic system is a major target of antidepressants
such as selective serotonin-reuptake inhibitor (SSRI)
fluoxetine and fluvoxamine. Recently, a novel antidepres-
sant mirtazapine has been developed and is now approved
in many countries for clinical treatment of major depres-
sion [12]. Mirtazapine is categorized into a noradrenergic
and specific serotonergic antidepressant (NaSSA), showing
multiple pharmacological actions such as inhibiting pre-
synaptic α2 noradrenaline receptor (NAR) and selectively
activating 5-HT1AR [13,14]. Mirtazapine has higher
antidepressant effects than placebo or trazodone, which is
equivalent to the effect of tricyclic antidepressant
(TCA) such as clomipramine and amitriptyline [15-17].
Compared to SSRI, mirtazapine showed an earlier onset
of antidepressant effects [18]. Further, the side effects of
mirtazapine are reported to be lower than those of SSRI
or TCA [19].
In 2004, Nakayama et al. reported mirtazapine increased
DA release in the medial prefrontal cortex (mPFC) of rats
with activating 5-HT1AR [20]. They reported that 8 or
16 mg/kg of mirtazapine increased DA release with
dose-dependent manner, and an inhibitor of 5-HT1AR
WAY100635 significantly decreased the mirtazapine-
induced increase of DA release. We hypothesized
mirtazapine may be effective on PD if the same mechan-
ism as this 5-HT-dependent increase of DA release existed
in the nigro-striatal dopaminergic system, too. In fact with
related to PD, some studies reported the clinical efficacy
of mirtazapine on Parkinsonian tremor in human [21,22].
However, little is known about the therapeutic effect of
mirtazapine for motor dysfunctions other than tremor in
PD. Therefore, in this study, we examined the effect
of mirtazapine in mice treated with the neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
one of the typical animal models of PD [23,24].Results
Effect of mirtazapine on motor dysfunctions induced by
MPTP
We first assessed effect of mirtazapine on motor dys-
functions induced by MPTP using two different behav-
ioral paradigms: the beam-walking and rota-rod tests.
We chose two doses of mirtazapine (4 and 16 mg/kg)
in this study based on the previous study by Nakayama
et al. in 2004 [20] in which they showed 4, 8 and 16 mg/kg
of mirtazapine produced a dose-dependent increase in
extracellular DA levels in mPFC of freely moving rats. Thus
we examined minimal (4 mg/kg) and maximal (16 mg/kg)
doses in mice.
In beam-walking test, MPTP-treated mice showed a
significantly prolonged duration to traverse a distance of
50 cm than that of the vehicle-treated mice (Figure 1A;
F (A) 4,44 = 9.803, P < 0.01, ANOVA). In contrast, mirta-
zapine significantly improved the MPTP-induced pro-
longation of the traversal duration when it was treated
after MPTP with both 4 and 16 mg/kg doses (Figure 1A;
P < 0.01, ANOVA), although it did not affect when solely
applied compared to the vehicle-treated mice (Figure 1A,
P > 0.05, ANOVA).
With rota-rod test, vehicle-treated mice usually remained
on the rotating rod for approximately 400–600 sec. As
shown in Figure 1B, MPTP-treatment significantly de-
creased the latency to fall from the rod when compared to
vehicle-treated mice (F (B) 4,44 = 7.341, P < 0.05, ANOVA).
On the other hand, administration of 16 mg/kg of mirta-
zapine after MPTP significantly recovered the latency to
the level of vehicle-treated group (Figure 1B; P < 0.05,
ANOVA), with no effect when solely applied.
Effect of mirtazapine on the striatal DA, DOPAC, HVA and
turnover rate
Using HPLC, we quantified the striatal DA and its me-
tabolites DOPAC (3,4-dihydroxyphenylacetic acid) and
HVA (homovanillic acid) with calculating turnover rate.
As shown in Figure 2, administrations of MPTP produced
marked depletion of DA, DOPAC and HVA in striatum
(F (DA) 4,20 = 15.423, F (DOPAC) 4,20 = 10.767, F (HVA) 4,20 =
6.643, P < 0.01, ANOVA), as was reported previously
[25,26]. DA turnover, calculated by (DOPAC +HVA)/DA
[26], was increased significantly by MPTP treatment com-
pared with vehicle (P < 0.01, Student’s t-test). Mirtazapine,
when solely applied with 16 mg/kg, showed no significant
alterations on them when compared with vehicle-treated
group (Figure 2; P > 0.05, ANOVA). Furthermore, admin-
istrations of mirtazapine after MPTP treatment also
showed no significant changes on them (Figure 2; P > 0.05,
ANOVA) both with 4 and 16 mg/kg. However, DA turn-
over was significantly increased by 16 mg/kg of mirtaza-
pine after MPTP treatment when compared with vehicle




















































Figure 1 Effects of mirtazapine on MPTP-induced motor dysfunctions in mice using beam-walking test and rota-rod test.
(A) Beam-walking test: Vertical axis shows the periods required to traverse 50 cm of the beam. (B) Rota-rod test: Vertical axis shows the
latency to fall from the rotating rod after the mice were placed on it. Values are expressed as means ± SEM, n = 9–10 mice/group. Mirt.(4),
mirtazapine 4 mg/kg; Mirt.(16), mirtazapine 16 mg/kg. Statistical significance was evaluated by one-way ANOVA followed by Scheffe test

























































Figure 2 Effects of mirtazapine on the striatal dopamine, DOPAC and HVA contents. Values are expressed as means ± SEM, n = 5 mice/group.
Mirt.(4), mirtazapine 4 mg/kg; Mirt.(16), mirtazapine 16 mg/kg. Statistical significance was evaluated by one-way ANOVA followed by
Student-Newman-Keuls test (F (DA) 4,20 = 15.423, F (DOPAC) 4,20 = 10.767, F (HVA) 4,20 = 6.643, F (Turnover) 4,20 = 4.951, *P < 0.05, **P < 0.01 compared with
MPTP-treated group) or by Student’s t-test (##P < 0.01 compared with vehicle group).
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when solely applied with 16 mg/kg (Figure 2; P > 0.05,
ANOVA).
Effect of mirtazapine on the striatal TH, DAT and VMAT2
protein expression
With western blot analysis, we examined protein expression
of the dopaminergic markers tyrosine hydroxylase (TH),
dopamine transporter (DAT) and vesicle monoamine trans-
porter 2 (VMAT2) in striatum. Treatment with mirtaza-
pine, when solely applied with 16 mg/kg, showed no
significant effects on the striatal TH, DAT and VMAT2
protein expression of mice when compared to the vehicle-
treated group (Figure 3A,B and C; F (TH) 4,17 = 16.115,
F (DAT) 4,17 = 12.386, F (VMAT2) 4,19 = 6.711, P > 0.05,
ANOVA), although VMAT2 expression showed a slight
tendency of decrease with no significance. MPTP signifi-
cantly decreased TH, DAT and VMAT2 protein expres-
sions to 20 – 50% of the vehicle treated ones (Figure 3A,
B and C; P < 0.01, ANOVA). Mirtazapine did not alter















































Figure 3 Effects of mirtazapine on the striatal TH, DAT and VMAT2 pr
(C), representative membrane image (upper panels) and the densitometric
VMAT2 (C). In (A), (B) and (C), actin protein was used as an internal contro
vehicle (means ± SEM), n = 4–5 mice/group. Mirt.(4), mirtazapine 4 mg/kg; M
one-way ANOVA followed by Scheffe test (F (TH) 4,17 = 16.115, F (DAT) 4,17 = 1
group) or by Student’s t-test (#P < 0.05 compared with MPTP-treated group(Figure 3A; P > 0.05, ANOVA), strongly suggesting it did
not affect the process of neurodegeneration of the nigro-
striatal dopaminergic neurons triggered by MPTP. In con-
trast, mirtazapine showed a dose-dependent tendency of
recovery of DAT protein expression, and 16 mg/kg of mir-
tazapine showed significant increase of DAT when com-
pared with MPTP-treated group (Figure 3B; P < 0.05,
Student’s t-test). Furthermore, both 4 and 16 mg/kg of mir-
tazapine showed significant recovery of VMAT2 protein
expression compared with MPTP-treated group (Figure 3C;
P < 0.01, ANOVA).
Antagonism of WAY100635 on the behavioral effects of
mirtazapine
One of the pharmacological effects of mirtazapine is a se-
lective activation of 5-HT1AR with blocking both 5-HT2
and 5-HT3 receptors. To examine the involvement of
this mechanism in the effects of mirtazapine, we tested
WAY100635, a specific antagonist for 5-HT1AR, together
with mirtazapine both on beam-walking and rota-rod





































otein expression examined by western blot analysis. (A), (B) and
analysis of the positive bands (lower graphs) of TH (A), DAT (B) and
l. Expression of TH, DAT and VMAT2 proteins are expressed as % of
irt.(16), mirtazapine 16 mg/kg. Statistical significance was evaluated by
2.386, F (VMAT2) 4,19 = 6.711 **P < 0.01 compared with MPTP-treated
).
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0.5 mg/kg of WAY100635 (Figure 4A and B; F (A) 3,35 =
18.962, F (B) 3,35 = 5.488, P < 0.01, ANOVA).
We also examined the effects of WAY100635 on the
basal activities of both tests, and it did not show any sig-
nificant effects when compared with vehicle-treated group
(Figure 5A and B; F (A) 3,36 = 14.476, F (B) 3,36 = 27.092,
P > 0.05, ANOVA).
Antagonism of prazosin or clonidine on the behavioral
effects of mirtazapine
Because noradrenergic system regulates both DA and 5-
HT neurons [27-29] and α2-NAR is one of an inhibitory
target of mirtazapine, we tested prazosin, an antagonist
for α1-NAR, or clonidine, selective agonist for α2-NAR,
together with mirtazapine both on beam-walking and
rota-rod tests. As shown in Figure 6A and B, both of
the noradrenergic drugs significantly reduced the ef-
fects of mirtazapine (Figure 6A and B; F (A) 4,45 = 15.060,
F (B) 4,45 = 13.097, P < 0.01, ANOVA), although their effect
in beam-walking test was incomplete when compared to
that of WAY100635.
As we did in the previous section using WAY100635,
we also examined both of the noradrenergic drugs on
the basal behavioral activities of beam-walking and rota-rod
tests. In beam-walking test, prazosin did not affect the pe-
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** 
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Figure 4 Inhibition of the behavioral effects of mirtazapine by WAY1
test: Vertical axis shows the periods required to traverse 50 cm of the beam
rotating rod after the mice were placed on it. Values are expressed as mea
by one-way ANOVA followed by (A) Scheffe test and (B) Student-Newman
compared with MPTP-treated group and †P < 0.05 compared with MPTP +increased it (Figure 5A; P < 0.01, ANOVA). In rota-rod test,
both prazosin and clonidine significantly shortened the
latency to fall from the rotating rod (Figure 5B; P < 0.01,
ANOVA), suggesting some of the effects we have observed
contain basal disturbance of these drugs on autonomic
system.
Antagonism of WAY100635, prazosin and clonidine on
the biochemical effects of mirtazapine
We also examined the effects of WAY100635, prazosin
and clonidine on the contents of the striatal DA and its
metabolites with turnover rate of DA by HPLC both in
the vehicle and MPTP-treated mice. As shown in Table 1,
all of three drugs have no effects on basal DA, DOPAC
and HVA contents, although prazosin and clonidine de-
creased basal DA turnover significantly when compared
with vehicle-treated group (Table 1; P < 0.05 and P < 0.01,
respectively, Student’s t-test). When these three drugs
were administered prior to mirtazapine, all of them signifi-
cantly reduced the increased DA turnover observed in
MPTP +mirtazapine group (Table 1; F (Turnover) 8,40 =
4.232, P < 0.05, ANOVA).
RT-PCR detection of mRNA for the isoforms of
noradrenaline and serotonin receptors
To examine whether the known receptors, which could


















Mirtazapine (16) - - + + 
WAY100635  - - - + 
MPTP (-) MPTP (+) 
** 
* 
00635 on beam-walking test and rota-rod test. (A) Beam-walking
. (B) Rota-rod test: Vertical axis shows the latency to fall from the
ns ± SEM, n = 9–10 mice/group. Statistical significance was evaluated
-Keuls test. (F (A) 3,35 = 18.962, F (B) 3,35 = 5.488, *P < 0.05, **P < 0.01
mirtazapine group).
Figure 5 Effects of WAY100635, prazosin or clonidine on basal motor activity of normal mice. (A) Beam-walking test: Vertical axis shows
the periods required to traverse 50 cm of the beam. (B) Rota-rod test: Vertical axis shows the latency to fall from the rotating rod after the mice
were placed on it. Values are expressed as means ± SEM, n = 10 mice/group. WAY, WAY100635; Praz, prazosin; Clon, clonidine. Statistical significance
was evaluated by one-way ANOVA followed by Scheffe test (F (A) 3,36 = 14.476, F (B) 3,36 = 27.092, **P < 0.01 compared with vehicle group).
Kadoguchi et al. BMC Neuroscience 2014, 15:79 Page 6 of 12
http://www.biomedcentral.com/1471-2202/15/79the inhibitors used in this study, are expressed in stri-
atum, SNc and raphe nucleus, we performed RT-PCR.
The specific primers used to detect mRNAs for the nor-
adrenaline and 5-HT receptors, α1A, α1B, α1D, α2A, α2B,
5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT3 are writ-
ten in Methods. As shown in Figure 7, α1A, α1B, α1D, α2A
and α2B noradrenaline receptors were expressed in stri-
atum, SNc and raphe. On the other hand, no 5-HT2BR
transcript was detected in SNc and raphe, while 5-HT1A,
5-HT2A, 5-HT2C and 5-HT3 receptors were detected in
striatum, SNc and raphe (Figure 7).
Discussion
In the present study, we found that treatment with mir-
tazapine in mice significantly improved MPTP-induced
motor dysfunction. To our knowledge, this is the first
report showing the therapeutic potency of an antidepres-
sant mirtazapine against MPTP neurotoxicity in mice.
Because MPTP mice are one of the most popular models
for screening anti-PD agents [23-26,30], our results sug-
gest possible use of mirtazapine as a PD therapeutics in
clinical patients.
Our results of HPLC in Figure 2 and Table 1 showed
MPTP increased DA turnover in striatum, and mirtazapine
further elevated it. Similar results were reported previously
by zonisamide, an anti-convulsant drug also effective on
PD [26]. Increased DA turnover with MPTP treatment is
thought as a compensatory effect exerted by the remained
DA neurons under the neurotoxic condition [26,31],
although significant behavioral deficits (Figure 1) sug-
gested the compensatory effect was insufficient to keepthe normal motor coordination. Further elevation of
DA turnover with mirtazapine after MPTP treatment
observed in this study led us to speculate mirtazapine
facilitate utilization of DA, probably by increasing DA
release, reuptake, degradation and/or recycling in the
DA-depleted condition. Supporting this idea, in fact, re-
duced protein expression of DAT by MPTP was partially
recovered, and that of VMAT2 was almost completely re-
covered to the normal level by mirtazapine (Figure 3B and
C). The increase of these transporter proteins would re-
flect the increased DA release from the dopaminergic
nerve terminals in striatum by mirtazapine [32,33]. In
contrast, reduction of TH expression with MPTP was not
rescued by mirtazapine (Figure 3A), suggesting it did not
affect on the neurodegenerative process of MPTP.
The effect of mirtazapine in our study was expressed
specifically after the treatment of MPTP, and the sole
treatment with mirtazapine did not alter the behavioral
parameters (Figure 1) nor the striatal contents of DA and
its metabolites with DA turnover (Figure 2 and Table 1),
whereas the previous report of Nakayama et al. [20]
showed increased DA release by acute and sole treatment
of mirtazapine in mPFC of rats. The discrepancy is prob-
ably caused by following differences: schedule of drug ad-
ministration, method and timing of sampling, method of
analysis especially because the lack of real-time measure-
ment of extracellular DA levels in our study. Nevertheless
of the discrepancy, these results suggest increase of DA by
mirtazapine in the rodent brain with a short-term admin-
istration. Other study, however, reported that two-week














































Figure 6 Inhibition of the behavioral effects of mirtazapine by prazosin or by clonidine. (A) Beam-walking test: Vertical axis shows the
periods required to traverse 50 cm of the beam. (B) Rota-rod test: Vertical axis shows the latency to fall from the rotating rod after the mice were
placed on it. Values are expressed as means ± SEM, n = 10 mice/group. Statistical significance was evaluated by one-way ANOVA followed by (A)
Student-Newman-Keuls test and (B) Scheffe test (F (A) 4,45 = 15.060, F (B) 4,45 = 13.097, *P < 0.05, **P < 0.01 compared with MPTP-treated group and
††P < 0.01, †P < 0.05 compared with MPTP +mirtazapine group).
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frontal cortex [34]. It may be possible that the pharmaco-
logical action of miratazapine is different depending on
the periods of administration and the amount of DA at
the targeted synapses. Further examination using microdi-
alysis in striatum measuring extracellular DA, NA and 5-
HT with their metabolites will explore more precise
mechanisms of both acute and chronic action of mirtaza-
pine including the hypothesis shown in Figure 8.Table 1 The effect of WAY100635, prazosin or clonidine on th
Dopam
Vehicle 19.49 ± 0
WAY100635 (0.05 mg/kg) 18.22 ± 1
prazosin (0.03 mg/kg) 20.27 ± 2
clonidine (0.15 mg/kg) 22.76 ± 1
MPTP 3.38 ± 0.
MPTP +mirtazapine (16 mg/kg) 1.90 ± 1.
MPTP +mirtazapine (16 mg/kg) + WAY100635 (0.05 mg/kg) 2.25 ± 0.
MPTP +mirtazapine (16 mg/kg) + prazosin (0.03 mg/kg) 3.49 ± 0.
MPTP +mirtazapine (16 mg/kg) + clonidine (0.15 mg/kg) 2.90 ± 0.
The results are shown as the mean (μg/g tissue) ± SEM of 4–6 animals/group. Statistica
F (DOPAC) 8,40 = 32.896, F (HVA) 8,40 = 29.578, F (Turnover) 8,40 = 4.232, *P < 0.05,**P < 0.01 com
group), or by Student’s t-test (#P < 0.05, ##P < 0.01 compared with vehicle group).As mentioned in Introduction, mirtazapine is categorized
into NaSSA, inhibiting pre-synaptic α2-NAR specifically.
Mirtazapine also inhibits 5-HT2 and 5-HT3 receptors
which in turn selectively activate 5-HT1R. It enhances,
therefore, the release of noradrenaline and 5-HT1AR-me-
diated serotonergic transmission [35]. Based on these
pharmacological properties of mirtazapine and from our
results of the experiments using NAR- and 5-HTR-related
reagents, we illustrated a hypothetical mechanism ofe striatal dopamine, DOPAC and HVA
ine DOPAC HVA Turnover rate
.75** 1.62 ± 0.12** 1.03 ± 0.04** 0.14 ± 0.01
.21** 1.73 ± 0.09** 0.91 ± 0.04** 0.15 ± 0.01
.33** 1.51 ± 0.14** 0.79 ± 0.09** 0.12 ± 0.01#
.88** 1.47 ± 0.07** 0.84 ± 0.05** 0.10 ± 0.01##
35 0.51 ± 0.05 0.44 ± 0.04 0.28 ± 0.01##
21 0.38 ± 0.08 0.29 ± 0.06 0.78 ± 0.25*
47 0.40 ± 0.10 0.32 ± 0.08 0.33 ± 0.05†
48 0.56 ± 0.04 0.37 ± 0.01 0.28 ± 0.03†
68 0.58 ± 0.68 0.45 ± 0.07 0.31 ± 0.04†
l significance was evaluated by Student-Newman-Keuls test (F (DA) 8,40 = 84.267,
pared with MPTP-treated group and †P < 0.05 compared with MPTP +mirtazapine











































Figure 7 RT-PCR detection of mRNAs for the isoforms of NA and 5-HT receptors. RT-PCR was performed as described in Methods. PCR
products were subjected to agarose gel electrophoresis, and the gel images with UV detection are shown.
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minergic system with serotonergic and noradrenergic
systems (Figure 8). WAY100635, a selective inhibitor
for 5-HT1AR, clearly cancelled the therapeutic effects of
mirtazapine on MPTP-induced neurotoxicity without af-
fecting the basal behavioral or the biochemical parameters
(Figures 4 and 5, Table 1), strongly suggest the involve-
ment of this receptor for the effects of mirtazapine. From
the dorsal raphe nuclei, 5-HT neurons innervate directly
to the nigral DA neurons to inhibit the firing of them with
5-HT2AR-dependent manner [28,36]. Inhibition of thisFigure 8 Hypothetical mechanisms of therapeutic effects against PD
NA, noradrenaline; GABA, γ-aminobutylic acid; MSN, medial spiny neuron; D
noradrenaline receptor; α2-NAR, α2 noradrenaline receptor; 5-HT1AR, 5-HT1A
innervation and receptors. The circle indicates a stimulatory effect by mirta
See details in Discussion.5-HT2AR by mirtazapine results in increase of DA re-
lease. Further, the recurrent innervation of 5-HT neu-
rons via 5-HT1AR in raphe negatively controls cell firing
and release of 5-HT [37]. Thus, activation of 5-HT1AR by
mirtazapine can reduce 5-HT release, and it also results in
the increased DA release. In fact, our RT-PCR results
showed expression of both 5-HT2AR mRNA in SNc and
5-HT1AR in raphe (Figure 7). Recently, it has been re-
ported that 5-HT2AR antagonists M100907 improved
motor impairments in the MPTP-induced mouse model
of PD [38]. Other studies also revealed that stimulation ofby mirtazapine. DA, dopamine, 5-HT, 5-hydroxytryptamine (serotonin);
1R, dopamine D1 receptor; D2R, dopamine D2 receptor; α1-NAR, α1
receptor: 5-HT2R, 5-HT2 receptor. Dashed lines indicate hypothetical
zapine, while the crosses indicate an inhibitory effect by mirtazapine.
Kadoguchi et al. BMC Neuroscience 2014, 15:79 Page 9 of 12
http://www.biomedcentral.com/1471-2202/15/795-HT1AR recovered the motor disorders caused by lesions
of DA neurons or DA depletion [39-42]. Thus, both 5-
HT1AR and 5-HT2AR are attractive targets as novel PD
therapeutics. α2-NAR is another inhibitory target of mirta-
zapine. In fact, clonidine, a selective agonist for this recep-
tor reduced the effects of mirtazapine, although it also
affected basal activity of mice and striatal DA turnover
(Figures 6 and 5, Table 1), probably of its inhibitory
effect on peripheral sympathetic system. Noradrenaline
inhibits the neurotransmitter release via presynaptic α2-
NAR, and mirtazapine increases neurotransmitter release
by inhibiting this receptor [13,14]. Although precise
mechanism is still unknown, we speculate this receptor
could also function as presynaptic hetero receptor on DA
neuron to regulate DA release negatively, the same as pre-
synaptic autoreceptor on noradrenergic nerve terminal
(Figure 8). Actually we detected α2A and α2B mRNA iso-
forms both in striatum and SNc (Figure 7). Prazosin, an
antagonist for α1-NAR, also showed similar effects as clo-
nidine. We suppose noradrenergic input on DA would ac-
tivate DA neuron via α1-NAR in SNc as illustrated in
Figure 8, since similar stimulatory mechanism was re-
ported in 5-HT and other neurons [43]. However, we
could not clearly discriminate peripheral and central ef-
fects of the noradrenergic drugs in this study. It will be
difficult to use clonidine (0.15 mg/kg) and prazosin
(0.03 mg/kg) to address the mechanism for mirtazapine
effect in this mouse model with a systemic administration.
Precise mechanism of the effect of mirtazapine through
noradrenergic system should be examined, with applying
more specific inhibitors directly into specific brain re-
gions, for example.
It is a well known fact that long-term treatment of ʟ-
dopa in PD patients causes various adverse side effects
such as wearing-off, dyskinesia, psychiatric symptoms,
and so on [44,45]. A recent study has demonstrated that
treatment with a SSRI fluoxetine significantly suppressed
ʟ-dopa-induced rotational behavior in 6-hydroxydopamine
(6-OHDA)-treated rats with 5-HT1AR-dependent manner
[46]. Furthermore, a selective α2-NAR antagonist fipame-
zole reduced ʟ-dopa-induced dyskinesias in MPTP-treated
monkeys [47]. These observations suggest that NaSSA mir-
tazapine could be a possible novel therapeutic drug for PD,
particularly in regard to avoiding the adverse side effects of
ʟ-dopa. Depression in PD patients is the most common
psychiatric disturbance [48], and SSRIs are now often used
for the treatment [49]. Recently, NaSSA is also used and
shown to be effective in the treatment of depression in
PD patients as well as SSRI [48,50]. However, the ef-
fect of NaSSA on motor dysfunction in PD patients is
still unknown. Together with these reports and our
results in this study, it is highly expected that mirtaza-
pine has dual therapeutic effects both on depression and
PD in humans. Our study here and further detailedexaminations will open the next door of clinical trial
to examine mirtazapine on PD.
Conclusion
Our present study provides the first evidence that mirta-
zapine has a therapeutic potency against MPTP neuro-
toxicity in mice. Because PD patients sometimes show
depression together, it is highly expected that mirtaza-




Male C57BL/6 mice (Nihon SLC Co., Shizuoka, Japan),
8 weeks of age, were used in this study. The animals were
housed in a controlled environment (23 ± 1°C, 50 ± 5% hu-
midity) and were allowed food and tap water ad libitum.
The room lights were on between 8:00 and 20:00. All han-
dlings and procedures of animal experiments were per-
formed in accordance with the National Institute of
Health guide for the care and use of Laboratory animals
(NIH Publications No. 8023, revised 1978), and approved by
the Committee for Animal Experiments of the University
of Tokushima (#10138).
Drug treatments
Mice were injected with 20 mg/kg of MPTP (Sigma-
Aldrich, St. Louis, MO, USA) or saline intraperitoneally
(i.p.) every 2 hr for a total of four injections, resulting in a
cumulative dose of 80 mg/kg, as described previously [51].
Mirtazapine (generously provided by Meiji Seika Pharma
Co., Ltd., Japan) was dissolved in 0.5% carboxymethyl-
cellulose, and was applied once a day with 4 or 16 mg/
kg i.p. started from 1 hr after the final MPTP treatment
for 4 days. WAY100635 (0.5 mg/kg, Sigma-Aldrich, St.
Louis, MO, USA), prazosin (0.03 mg/kg, Sigma-Aldrich,
St. Louis, MO, USA) and clonidine (0.15 mg/kg, Sigma-
Aldrich, St. Louis, MO, USA) were dissolved in saline, and
each of them was administered 1 hr before treating with
mirtazapine.
Behavioral testing
Three days after MPTP or saline treatment, behav-
ioral tests were performed 1 hr after the final treat-
ment with mirtazapine or vehicle. For the behavioral
analysis, we examined with two different experimental
paradigms.
Beam-walking test
The apparatus used in this experiment was a modification
of that used by Allbutt and Henderson [52]. Before MPTP
treatment, mice were trained to transverse a wooden
round beam with 12 mm diameter, 80 cm length, sus-
pended 55 cm above the floor, in two consecutive trains
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MPTP or saline treatment, mice were subjected to trials
on the beam with 8 mm rather than 12 mm diameter dur-
ing which they were video-recorded. The time to reach a
distance of 50 cm was measured.
Rota rod test
The Rota rod treadmill (Constant Speed Model, Ugo Basile,
Varese, Italy) consists of a plastic rod, 6 cm in diameter and
36 cm long, with a non-slippery surface 20 cm above the
base (trip plate). This rod is divided into five equal sections
by six discs (25 cm in diameter), which enables five mice to
walk on the rod at the same time. In the present study,
rotor mode with a constant speed was used. All the mice
used were subjected to one training session a day for 3 con-
secutive days before MPTP treatment with 20 rpm for
10 min. At the trial session performed 3 days after MPTP
treatment, the latency to fall of the animals from the rotat-
ing rod (32 rpm for 10 min) after they were placed on it
was recorded as the performance time, as described previ-
ously [25].
Quantification of DA and its metabolites
The mice were killed by cervical dislocation 3 days after
the final treatment with saline or MPTP. The striatum
were rapidly dissected out on ice and sonicated in ice-cold
50 nM perchloric acid containing 1 μg/ml isoproterenol as
an internal standard. DA, DOPAC and HVA were quanti-
fied by HPLC with an electrochemical detector (ECD)
(Eicom, Kyoto, Japan). Concentrations of dopamine and its
metabolites were expressed as μg/g tissue weight, as de-
scribed previously [53,54].
Western blot analysis
The striatal tissues were homogenized in (50 mM Tris–
HCl, pH 7.5, 0.5 M NaCl, 0.5% Triton X-100, 10 mM
EDTA, 4 mM EGTA, 1 mM Na3VO4, 30 mM Na4P2O7,
50 mM NaF, 0.1 mM leupeptin, 0.075 mM pepstatin A,
0.05 mg/ml trypsin inhibitor, 1 mM phenylmethanesul-
fonyl fluoride, 100 nM calyculin A, and 1 mM dithio-
threitol) using a microtube homogenizer. Insoluble
materials were removed by centrifugation at 15,000 rpm
(CT15RE, HITACHI, Ibaragi, Japan) for 10 min. The su-
pernatants were mixed with Laemmli's sample buffer
(final concentrations, 63 mM Tris–HCl, pH 6.8, 2%
SDS, 5% β-mercaptoethanol, 2.5% glycerol, and 0.0083%
bromphenol blue) and boiled for 5 min. Protein concen-
trations of the sample were determined using the Bradford
protein assay. Ten micrograms of protein from each
sample were separated on 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel using
constant current. Separated proteins were transferred to
polyvinylidene difluoride (PVDF) membranes at 75 V for
1.5 hr using a Trans Blot Cell (Bio-Rad, CA, USA). Themembranes were incubated for 1 h at room temperature
with Tris-buffered saline containing 0.1% Tween 20 (TBST)
and 0.5% skim milk, followed by overnight incubation at
4°C with desired primary antibodies. The anti-TH anti-
body (1:1000, Chemicon International, Inc., Temecula,
CA, USA) and anti-DAT antibody (1:1000, Chemicon
International Inc., Temecula, CA, USA) as a marker of
dopaminergic neurons were used. The anti-VMAT2 anti-
body (1:500, Santa Cruz Biotechnology, CA, USA) as a
maker of presynaptic components was used. Membranes
were washed six times for 5 min each at room temperature
and incubated with horseradish peroxidase-conjugated sec-
ondary antibody in TBST for 1 hr. Immunoreactive bands
were visualized by enhanced chemiluminescent autoradi-
ography (ECL Kit, GE healthcare, Buckinghamshire, UK),
according to manufacturer’s instructions. Actin antibody
(Sigma, Saint Louis, MO, USA) was used as a house
keeping protein to confirm that equal amounts of pro-
tein were loaded in each line. Optical densities were de-
termined using a computerized image analysis system
(Dolphin-DOC, Kurabo, Osaka, Japan), as described
previously [25,55].
RNA isolation and RT-PCR
Total RNA from striatum, SNc or raphe was purified
using RNAiso plus (Takara Bio, Tokyo, Japan) according
to manufacturer’s protocol. Reverse transcription from
RNA to cDNA was performed using M-MLV reverse tran-
scriptase and other supplements (Promega, Madison, WI,
USA). Polymerase chain reaction (PCR) with GoTaq
Green (Promega, Madison, WI, USA) was performed with
using glyceraldehyde phosphate dehydrogenase (GAPDH)
as an internal control. The following primers for mouse
noradrenaline and 5-HT receptors with GAPDH were
used (name, accession number, forward (F) or reverse (R)
primer sequence, product length):
α1A, NM_07417, (F) CGACAAGTCAGACTCAGAG
CAAGTGA,
(R) TGTAGCCCAGGGCATGCTTGGAAGAC, 403 bp;
α1B, NM_007416, (F) TTTCATGAGGACACCCTCA
GCAGTACC,
(R) CTGCCACTGTCATCCAGAGAGTCC, 451 bp;
α1D, NM_013460, (F) CGCCAAAGGAAATCCAGGG
ACAC,
(R): CAGAGCGGAACTTATGGGACAGG, 616 bp;
α2A, NM_013461, (F) TTCTTTTTCACCTACACGC
TCA,
(R) TGTAGATAACAGGGTTCAGCGA, 121 bp;
α2B, NM_009633, (F) ACCTTCCCTTGCTGACTGT
ACT,
(R) TGGGAGGGAGGTATTCTAATCA, 111 bp;
5HT1A, NM_008303, (F) TGCTCATGCTGGTCCTC
TAT,
(R) TCTCAGCACTGCGCCTGC, 179 bp;
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ATTGATG,
(R) TGATTTTCAGGAAGGCTTTGGTT, 477 bp;
5HT2B, NM_008311, (F) CTCGGGGGTGAATCCTC
TGA,
(R) CCTGCTCATCACCTCTCTCAG, 366 bp;
5HT2C, NM_008312, (F) CAGATCAGAAGCCACGT
CGA,
(R) GGCTTATAATCGCAGCGCAA, 318 bp;
5HT3, NM_013561, (F) GCCACCCAGGCCCGAGA
TAC,
(R) GCTCCCACTCGCCCTGATTT, 564 bp;
GAPDH, M32599, (F) GCCAAAGGTCATCCATGA
CAACTTTG,
(R) CATTGGGGGTAGGAACACGGAAGGC, 237 bp;
All of the PCR reactions were started with heating
95°C for 2 min, followed by the repeated cycle of 95°C
for 30 sec, 57 - 61°C for 45 sec and 72°C for 1 min, with
additional 72°C for 10 min. After repeated thermal reac-
tions for 30 cycles, the PCR products were separated by
gel electrophoresis with 1% agarose containing 5 μg/mL of
ethidium bromide.
Statistical analysis
All values were expressed as the means ± SEM and stat-
istical significance was evaluated by one-way analysis of
variance (ANOVA) followed by Scheffe test, Student-
Newman-Keuls test or Student’s t-test (Stat View version
5.0, SAS Institute Inc., USA). Statistical differences were
considered with significance at P < 0.05.Abbreviations
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